Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial

CNBC December 4, 2024
Annika Kim Constantino

Key Points

– Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk’s Wegovy, in the first head-to-head clinical trial on the two weekly injections.

– The findings suggest Zepbound may be a superior treatment for weight loss, helping patients with obesity or who are overweight lose 20.2% of their body weight on average after 72 weeks.

– Wegovy helped people lose 13.7% of their weight on average after the same time period.

Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk‘s Wegovy, in the first head-to-head clinical trial on the weekly injections.

The findings suggest Zepbound may...

Today's Sponsors

Today's Sponsor